The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Sep. 24, 11:50 AM

Slide #24. Array BioPharma Inc. Secondary Offering

Company: Array BioPharma Inc. (NASDAQ:ARRY)
Date announced: 9/13/2017
Shares Offered: 20,930,232
Date of Pricing: 9/14/2017
Price Per Share: $10.75
Secondary Offering Details: Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma. -updated 8/14- Array BioPharma Inc. (Nasdaq: ARRY) announced today the pricing of an underwritten public offering of 20,930,232 shares of its common stock at a public offering price of $10.75 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and offering expenses, are expected to be approximately $225 million. The offering is expected to close on or about September 19, 2017, subject to customary closing conditions. Array also granted the underwriters a 30-day option to purchase up to 3,139,534 additional shares of common stock. All of the shares sold in the offering are being sold by Array.

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Co.'s clinical stage drugs include: Binimetinib and Selumetinib, MEK inhibitors for cancer; Encorafenib, a BRAF inhibitor for cancer; ASC08/Danoprevir, a protease inhibitor for hepatitis C virus; Ipatasertib/GDC-0068, a AKT inhibitor for cancer; Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer; and ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy, among others.

ARRY SEC Filing Email Alerts Service

Open the ARRY Page at The Online Investor »

Company Name:  Array BioPharma Inc.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ARRY:  24
Total Market Value Held by ETFs:  $138.83M
Total Market Capitalization:  $1.99B
% of Market Cap. Held by ETFs:  6.98%

Open the ARRY Page at The Online Investor (in a new window) »

September 24, 2017    11:50 AM Eastern
Quotes delayed 20 minutes

Strong Buy (3.78 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.